However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, researchers found after reviewing data from dozens of clinical trials.
Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.